In Alzheimer's disease (AD), PKCε activators, cyclopropanated fatty acid derivatives DCP-LA and DHA-CP6, have been found to reduce amyloid β levels by enhancing the degradation of amyloid precursor protein (APP) [15], whereas overexpression of APP in turn decreases the levels of both membrane-bound active PKCε and cytosolic inactive PKCε in three different cell lines [16]. This evidence concerns the gene PRKCE and early-onset autosomal dominant Alzheimer disease.